This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Otsuka Pharmaceutical Company, Limited. Active years: 2000-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Tokushima-ken, JP (2000)
- Osaka, JP (2015)
Company Filing History:
Years Active: 2000-2015
Title: Hisanobu Hirano: Innovator in Stem Cell Research
Introduction
Hisanobu Hirano is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of stem cell research, focusing on therapeutic applications. With a total of 2 patents, his work is paving the way for advancements in regenerative medicine.
Latest Patents
Hirano's latest patents include a groundbreaking invention related to stem cells derived from human monocytes. This invention details a method for inducing stem cells by culturing monocytes in the presence of M-CSF and at least one member selected from the group consisting of ganglioside and water-soluble plant-derived extract. The patent outlines various applications, including a therapeutic agent for treating damaged cells, tissues, or organs, a cell drug agent, and a culture medium for dedifferentiating monocytes. Additionally, he has worked on a patent involving the FK506-binding protein gene.
Career Highlights
Hirano is currently associated with Otsuka Pharmaceutical Company, Limited, where he continues to innovate in the field of biotechnology. His work has garnered attention for its potential to revolutionize treatments for various medical conditions.
Collaborations
Hirano collaborates with notable colleagues, including Yasushi Ohkubo and Kenjiro Sasaki, contributing to a dynamic research environment that fosters innovation.
Conclusion
Hisanobu Hirano's contributions to stem cell research exemplify the impact of innovative thinking in medicine. His patents reflect a commitment to advancing therapeutic techniques that could benefit countless individuals in need of regenerative treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile